The Lung Cancer Surgery Market is estimated to be valued at US$ 6.40 billion in 2023 and is expected to exhibit a CAGR of 5.8% over the forecast period from 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Lung cancer surgery is a medical procedure that is conducted in order to teat lung cancer, especially non-small cell lung cancer. Lung cancer is also referred to as lung carcinoma and is a lethal lung tumor. It is attributed with simultaneous multiplication of tumor cells leading in uncontrolled growth of cells in the lung tissues and is malignant in nature. Caused mainly due to excessive growth of the abnormal cancerous cells in lung area and factors such as smoking, passive smoking in few cases, exposure to carcinogenic toxins and gases and others are responsible for increasing risk of this disease. Primary lung cancer is referred to as carcinomas that initiates in the lungs while secondary lung cancer starts in other body parts and eventually reaches lungs. The lung cancer is detected and confirmed with the help of biopsy that is conducted using CT-guidance or bronchoscopy. Lung cancer surgery is the surgical ablation of cancer tissue from the lung. The type of surgery in lung cancer management is dependent on the position and size of tumor.
Ask For A Sample Report: https://www.coherentmarketinsights.com/insight/request-sample/6146
The Lung Cancer Surgery Market involves surgical procedures for the treatment of lung cancer. The market is driven by the increasing prevalence of lung cancer globally. According to the World Health Organization (WHO), lung cancer is the leading cause of cancer-related deaths worldwide, accounting for 1.8 million deaths in 2020. The development of innovative surgical techniques and technological advancements in surgical equipment and procedures is further fueling market growth. Lung cancer surgery offers benefits such as improved outcomes, reduced hospital stays, and increased chances of survival. Moreover, the use of minimally invasive procedures, such as video-assisted thoracoscopic surgery (VATS) and robotic-assisted surgery, is gaining popularity, leading to shorter recovery times and improved patient outcomes.
Competitive Analysis
Key players profiled in the report: Ethicon (Johnson & Johnson), Medtronic, Intuitive Surgical, Olympus Corporation, Karl Storz, Teleflex Incorporated, Accuray Incorporated, AngioDynamics, CONMED Corporation, Trovagene, Varian Medical Systems, Medrobotics Corporation, Siemens Healthineers, Atricure, Inc., Novadaq Technologies Inc.
Market Dynamics:
The market dynamics driving the growth of the lung cancer surgery market can be attributed to two main factors. Firstly, the increasing prevalence of lung cancer is a significant driver for the market. The rising incidence of lung cancer is primarily due to risk factors such as smoking, exposure to environmental pollutants, and genetic predisposition. The demand for lung cancer surgery is expected to increase as the cases of lung cancer continue to rise.
Secondly, technological advancements in surgical procedures are contributing to market growth. Innovations in surgical techniques, such as minimally invasive procedures and robotic-assisted surgery, have revolutionized lung cancer surgery. These advancements offer benefits such as reduced trauma, shorter hospital stays, faster recovery times, and improved patient outcomes.
Detailed Segmentation:
By Surgery Type: Open Surgery, Minimally Invasive Surgery
By Procedure: Lobectomy, Segmentectomy/Wedge Resection, Pneumonectomy, Sleeve Resection, Extended Resection
By Cancer Stage: Early-Stage, Advanced-Stage
By Approach: Curative Surgery, Palliative Surgery
By Technology: Conventional Surgery, Minimally Invasive Surgery
By End User: Hospitals, Ambulatory Surgical Centers, Specialty Clinics
By Patient Demographics: Age, Health Status, Genetic Factors
By Emerging Trends and Innovations: Precision Medicine, Telemedicine
Click to Buy & Get Up To 25 % Off @ https://www.coherentmarketinsights.com/insight/buy-now/6146
Market Drivers for the Lung Cancer Surgery Market
- Increasing Prevalence and Incidence of Lung Cancer
The primary driver for the lung cancer surgery market is the increasing prevalence and incidence of lung cancer worldwide. Lung cancer is the leading cause of cancer-related deaths globally, and its incidence is growing at an alarming rate, particularly in developing countries. According to the World Health Organization (WHO), approximately 2.21 million new cases of lung cancer were diagnosed in 2020, accounting for 11.4% of all cancer cases.
The rising prevalence of lung cancer is primarily attributed to factors such as smoking, air pollution, and exposure to occupational hazards. As the number of diagnosed cases continues to rise, there is an increasing demand for accurate and efficient surgical procedures to treat lung cancer patients. This drives the growth of the lung cancer surgery market as healthcare providers invest in advanced surgical technologies and techniques to improve patient outcomes.
- Technological Advancements in Surgical Techniques and Equipment
Technological advancements in surgical techniques and equipment have transformed the landscape of lung cancer surgery. Traditional open surgeries have been largely replaced by minimally invasive techniques such as video-assisted thoracoscopic surgery (VATS) and robotic-assisted surgery, offering numerous benefits over conventional approaches.
Minimally invasive surgeries result in smaller incisions, reduced blood loss, shorter hospital stays, and faster recovery times compared to open surgeries. Additionally, these techniques provide improved visualization, precision, and manipulation of surgical instruments, leading to better surgical outcomes and patient satisfaction.
Furthermore, the integration of advanced imaging and navigation technologies into surgical systems allows for accurate pre-operative planning and intraoperative guidance, enhancing the surgeon’s ability to perform complex lung cancer surgeries. These advancements have significantly contributed to the growth of the lung cancer surgery market by improving patient outcomes and reducing the overall healthcare burden.
Market Restraints for the Lung Cancer Surgery Market
- High Cost of Surgical Procedures and Equipment
One of the major restraints for the lung cancer surgery market is the high cost associated with surgical procedures and equipment. Minimally invasive surgeries, while offering several benefits, require specialized instruments and equipment, which can be expensive. Additionally, the comprehensive training required to perform these surgeries adds to the overall cost.
Moreover, the cost of lung cancer treatment is further amplified by the need for pre-operative imaging, post-operative care, and follow-up procedures. This puts a significant financial burden on patients, especially in countries with limited healthcare resources and inadequate insurance coverage. Consequently, the high cost of lung cancer surgeries acts as a restraint, limiting access to advanced surgical treatments and hindering market growth.
- Complex Regulatory and Reimbursement Landscape
The complex regulatory and reimbursement landscape poses a significant challenge to the growth of the lung cancer surgery market. Obtaining regulatory approvals for new surgical techniques and equipment can be a lengthy and costly process, delaying their introduction into the market. Similarly, gaining appropriate reimbursement for lung cancer surgeries from public and private insurance providers can be challenging due to the lack of standardized pricing and reimbursement policies.
The reimbursement landscape varies across regions, with different countries adopting different reimbursement models and policies. This variability in reimbursement practices creates uncertainty for healthcare providers and impacts their willingness to invest in advanced surgical technologies. Furthermore, the complexity of regulatory and reimbursement processes adds administrative burden and can discourage healthcare providers from adopting new surgical techniques, thereby restraining market growth.
In conclusion, the increasing prevalence and incidence of lung cancer, coupled with technological advancements in surgical techniques and equipment, are the key drivers for the lung cancer surgery market. However, the high cost of surgical procedures and equipment, along with the complex regulatory and reimbursement landscape, act as restraints, hindering market growth. Addressing these challenges and ensuring affordable access to advanced surgical treatments is crucial to improve patient outcomes and drive the growth of the lung cancer surgery market.
Customize Your Report Now: https://www.coherentmarketinsights.com/insight/request-customization/6146
Check Out More Report:
Virtual Clinical Trials Market
Cervical Spondylosis Treatment Market
Medical Implants Market
Medical Billing Outsourcing Market
Plant Tissue Analysis Market
Long Term Care Market
Body Temperature Monitoring Market
Aesthetic Thread Market
Butterfly Needles Market
Ventilator Breathing Circuit Market
Drug Delivery Device Market
External Fixators Market
Blood Pressure Monitoring Testing Market
Ampoules and Syringes Market
𝐀𝐛𝐨𝐮𝐭 𝐔𝐬:
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having sales office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 57 countries worldwide. We create value for clients through our highly reliable and accurate reports. We are also committed in playing a leading role in offering insights in various sectors post-COVID-19 and continue to deliver measurable, sustainable results for our clients.
Contact Us:
Mr. Shah
Coherent Market Insights Pvt. Ltd,
533 Airport Boulevard, Suite 400, Burlingame, CA 94010, United States
✉Email: sales@coherentmarketinsights.com
📞United States of America: +1-206-701-6702
📞United Kingdom: +44-020-8133-4027
📞Japan: +050-5539-1737
📞India: +91-848-285-0837